These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1920812)

  • 41. [Clinical studies on imipenem/cilastatin sodium in the field of obstetrics and gynecology in the perinatal period].
    Tateno M
    Jpn J Antibiot; 1988 Nov; 41(11):1786-91. PubMed ID: 3210309
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical studies on imipenem/cilastatin sodium in perinatal use].
    Chimura T; Morisaki N; Hirayama T; Matsuo M
    Jpn J Antibiot; 1988 Nov; 41(11):1751-7. PubMed ID: 3210306
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Chemotherapy with imipenem/cilastatin for severe infections accompanied by malignant hematological disorders].
    Fujii Y; Inoue Y; Hiroshige Y; Kaku K; Kaneko T
    Jpn J Antibiot; 1993 Mar; 46(3):259-68. PubMed ID: 8510323
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vertigo caused by intravenous imipenem/cilastatin.
    Duque A; Altimiras J; García-Cases C; Vidal P
    DICP; 1991 Sep; 25(9):1009. PubMed ID: 1949961
    [No Abstract]   [Full Text] [Related]  

  • 45. Pharmacokinetics of imipenem-cilastatin following intravenous administration in healthy adult horses.
    Orsini JA; Moate PJ; Boston RC; Norman T; Engiles J; Benson CE; Poppenga R
    J Vet Pharmacol Ther; 2005 Aug; 28(4):355-61. PubMed ID: 16050815
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.
    Dreetz M; Hamacher J; Eller J; Borner K; Koeppe P; Schaberg T; Lode H
    Antimicrob Agents Chemother; 1996 Jan; 40(1):105-9. PubMed ID: 8787889
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of imipenem after intravenous, intramuscular and subcutaneous administration to cats.
    Albarellos GA; Denamiel GA; Montoya L; Quaine PC; Lupi MP; Landoni MF
    J Feline Med Surg; 2013 Jun; 15(6):483-7. PubMed ID: 23253883
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Imipenem/cilastatin sodium alone or combined with amikacin sulfate in respiratory infections].
    Takamoto M; Ishibashi T; Toyoshima H; Tanaka H; Tamaru N; Watanabe K; Yoshida M; Tokunaga N; Ichikawa Y; Oizumi K
    Jpn J Antibiot; 1994 Sep; 47(9):1131-44. PubMed ID: 7990255
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial.
    Bradley JS; Makieieva N; Tøndel C; Roilides E; Kelly MS; Patel M; Vaddady P; Maniar A; Zhang Y; Paschke A; Chen LF
    J Clin Pharmacol; 2023 Dec; 63(12):1387-1397. PubMed ID: 37562063
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics of imipenem/cilastatin sodium in children with peritonitis.
    Claesson G; Eriksson M; Rogers JD
    Pharmacol Toxicol; 1992 Aug; 71(2):103-6. PubMed ID: 1438026
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical evaluation of imipenem/cilastatin sodium in the internal medicine].
    Fukuhara H; Kusano N; Nakamura H; Kaneshima H; Irabu Y; Shimozi K; Kitukawa K; Shigeno Y; Saito A; Kakazu T
    Jpn J Antibiot; 1991 Aug; 44(8):877-85. PubMed ID: 1920813
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Clinical evaluation of imipenem/cilastatin sodium in infectious complications of hematological malignancies. Tohkai Research Group on Infections in Hematological Disorders].
    Naito K; Kobayashi M; Okumura M; Ikeda Y; Mitomo Y; Oguri T; Tanaka M; Ohara K; Kodera Y; Ohno R
    Jpn J Antibiot; 1990 Aug; 43(8):1371-80. PubMed ID: 2283705
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intramuscular imipenem as adjuvant therapy for acute cholecystitis and perforated or gangrenous appendicitis.
    Yellin AE; Heseltine PN; Berne TV; Appleman MD; Gill MA; Chenella FC
    Chemotherapy; 1991; 37 Suppl 2():37-43. PubMed ID: 1879186
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Tolerance and safety of carbapenems: the use of meropenem].
    Lizasoaín M; Noriega AR
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():73-7. PubMed ID: 9410074
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration.
    Boucher BA; Hudson JQ; Hill DM; Swanson JM; Wood GC; Laizure SC; Arnold-Ross A; Hu ZY; Hickerson WL
    Pharmacotherapy; 2016 Dec; 36(12):1229-1237. PubMed ID: 27862103
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A cost comparison of intramuscular versus intravenous imipenem.
    Chin A; Gill MA; Ito MK; Yellin AE; Berne TV; Heseltine PN; Appleman MD
    Hosp Pharm; 1989 Nov; 24(11):905-9. PubMed ID: 10296145
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
    Brismar B; Malmborg AS; Tunevall G; Lindgren V; Bergman L; Mentzing LO; Nyström PO; Anséhn S; Bäckstrand B; Skau T
    J Antimicrob Chemother; 1995 Jan; 35(1):139-48. PubMed ID: 7768761
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Imipenem/cilastatin sodium and other beta-lactams for respiratory tract infections: clinical benefit and treatment days for cure].
    Oizumi K; Rikimaru T; Shiraishi T; Motohiro A; Yoshida M; Watanabe K; Maruyama R; Ishibashi T; Kitahara Y; Kido M; Yoshii C; Hara N; Ikeda A; Yamada H; Ninomiya K; Matsuzaki Y; Ichinose Y; Namba K; Kodama T; Kunitake R; Miyazaki N; Abe K; Matsunaga R; Ide H; Kamae I
    Jpn J Antibiot; 1999 Jan; 52(1):1-15. PubMed ID: 10202683
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
    Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A;
    J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [A comparative study of imipenem/cilastatin sodium BID vs QID in the treatment of infections associated with hematopoietic disorders].
    Sawae Y; Niho Y; Okamura T; Murakawa M; Teshima T; Fujisaki T; Ikeda K; Kozuru M; Uike N; Katsuno M
    Jpn J Antibiot; 1994 Oct; 47(10):1318-28. PubMed ID: 7807693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.